Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition (Tables)

v3.21.1
Revenue Recognition (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
March 31, 2021 December 31, 2020
Current pharma contract assets (1)
$ 2,014  $ 1,643 
Long-term pharma contract assets (2)
355  290 
Total pharma contract assets $ 2,369  $ 1,933 
Current pharma capitalized commissions (1)
$ 182  $ 185 
Long-term pharma capitalized commissions (2)
1,020  970 
Total pharma capitalized commissions $ 1,202  $ 1,155 
Current pharma contract liabilities $ 3,992  $ 4,029 
Long-term pharma contract liabilities (3)
705  712 
Total pharma contract liabilities $ 4,697  $ 4,741 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended March 31,
2021 2020
Clinical Services:
    Client direct billing $ 60,709  $ 54,292 
    Commercial Insurance 18,574  21,993 
    Medicare and Medicaid 17,150  16,483 
    Self-Pay 54  214 
Total Clinical Services $ 96,487  $ 92,982 
Pharma Services: 19,046  13,048 
Total Revenue $ 115,533  $ 106,030